CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $80,128,453
- in 11 filings, $80.1M under 10b5-1 plans
Net −$80,128,453. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-15 | Inrig Jula EVP, Head of R&D & CMO | Option exercise 10b5-1 | +32,395 | $8.93 | $289K | 145,165 |
| 2026-09-15 | Inrig Jula EVP, Head of R&D & CMO | Sale 10b5-1 | −25,390 | $62.02 | $1.6M | 119,775 |
| 2026-09-15 | Inrig Jula EVP, Head of R&D & CMO | Sale 10b5-1 | −17,284 | $62.62 | $1.1M | 102,491 |
| 2026-09-15 | Inrig Jula EVP, Head of R&D & CMO | Sale 10b5-1 | −1,600 | $63.69 | $102K | 100,891 |
| 2026-09-15 | Inrig Jula EVP, Head of R&D & CMO | Sale 10b5-1 | −400 | $65.31 | $26K | 100,491 |
| 2026-09-15 | Inrig Jula EVP, Head of R&D & CMO | Option exercise · Employee stock option (right to buy) 10b5-1 | −32,395 | 43,605 | ||
| 2026-09-15 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 | +2,500 | $27.50 | $69K | 44,853 |
| 2026-09-15 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 | +1,250 | $22.40 | $28K | 46,103 |
| 2026-09-15 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 | +1,625 | $20.46 | $33K | 47,728 |
| 2026-09-15 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −4,275 | $62.14 | $266K | 43,453 |
| 2026-09-15 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −800 | $62.85 | $50K | 42,653 |
| 2026-09-15 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −300 | $63.66 | $19K | 42,353 |
| 2026-09-15 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −2,500 | 0 | ||
| 2026-09-15 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −1,250 | 3,750 | ||
| 2026-09-15 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −1,625 | 17,875 | ||
| 2026-09-15 | Heerma Peter EVP, CHIEF COMMERCIAL OFFICER | Option exercise 10b5-1 | +39,283 | $26.88 | $1.1M | 181,349 |
| 2026-09-15 | Heerma Peter EVP, CHIEF COMMERCIAL OFFICER | Option exercise 10b5-1 | +1,381 | $22.40 | $31K | 182,730 |
| 2026-09-15 | Heerma Peter EVP, CHIEF COMMERCIAL OFFICER | Option exercise 10b5-1 | +36,526 | $8.93 | $326K | 219,256 |
| 2026-09-15 | Heerma Peter EVP, CHIEF COMMERCIAL OFFICER | Sale 10b5-1 | −71,938 | $62.05 | $4.5M | 147,318 |
| 2026-09-15 | Heerma Peter EVP, CHIEF COMMERCIAL OFFICER | Sale 10b5-1 | −27,421 | $62.59 | $1.7M | 119,897 |
Page 3 of 41 · 802 trades